Literature DB >> 14525543

Epidemiological risk factors for hypersensitivity reactions to abacavir.

P J Easterbrook1, A Waters, S Murad, N Ives, C Taylor, D King, A Vyakarnam, D Thorburn.   

Abstract

We investigated risk factors for hypersensitivity reactions (HSR) to abacavir in a case-control study. In a multivariate analysis, white race [odds ratio (OR), 5.16; 95% confidence interval (CI), 1.16-22.97] and a higher CD8 cell count at initiation of abacavir (>850 vs. < or =850 cells: OR, 3.74; 95% CI, 1.19-11.77) were found to be significantly associated with the development of HSR. Age, gender, stage of disease, prior antiretroviral exposure and type of concurrent antiretroviral therapy were not associated with HSR. Differences in predisposition to HSR according to ethnicity and baseline CD8 cell count may be explained by the reported MHC genetic associations with HSR.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14525543     DOI: 10.1046/j.1468-1293.2003.00166.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  9 in total

Review 1.  Pharmacogenetics as a tool to tailor antiretroviral therapy: A review.

Authors:  Antonio Aceti; Laura Gianserra; Lara Lambiase; Alfredo Pennica; Elisabetta Teti
Journal:  World J Virol       Date:  2015-08-12

2.  Abacavir/lamivudine combination in the treatment of HIV: a review.

Authors:  Geetha Sivasubramanian; Emmanuel Frempong-Manso; Rodger D Macarthur
Journal:  Ther Clin Risk Manag       Date:  2010-03-03       Impact factor: 2.423

Review 3.  Antiretroviral treatment of maternal HIV infection.

Authors:  Haleh Talaie; Alejandro A Nava-Ocampo; Gideon Koren
Journal:  Can Fam Physician       Date:  2004-06       Impact factor: 3.275

4.  Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant.

Authors:  Annalise M Martin; David Nolan; Silvana Gaudieri; Coral Ann Almeida; Richard Nolan; Ian James; Filipa Carvalho; Elizabeth Phillips; Frank T Christiansen; Anthony W Purcell; James McCluskey; Simon Mallal
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-15       Impact factor: 11.205

Review 5.  The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions.

Authors:  Patricia T Illing; Anthony W Purcell; James McCluskey
Journal:  Immunogenetics       Date:  2017-07-10       Impact factor: 3.330

Review 6.  New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity.

Authors:  Munir Pirmohamed; David A Ostrov; B Kevin Park
Journal:  J Allergy Clin Immunol       Date:  2015-08       Impact factor: 10.793

Review 7.  Current perspectives in HIV post-exposure prophylaxis.

Authors:  Binta Sultan; Paul Benn; Laura Waters
Journal:  HIV AIDS (Auckl)       Date:  2014-10-24

Review 8.  Drug hypersensitivity in human immunodeficiency virus-infected patient: challenging diagnosis and management.

Authors:  Evy Yunihastuti; Alvina Widhani; Teguh Harjono Karjadi
Journal:  Asia Pac Allergy       Date:  2014-01-31

9.  HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia.

Authors:  Ernesto Martínez Buitrago; José Millán Oñate; José Fernando García-Goez; Jorge Álvarez; William Lenis; Luz Marina Sañudo; Luisa Consuelo Rubiano
Journal:  BMC Infect Dis       Date:  2019-09-09       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.